Abstract
Basics of Compounding for Cough
Author(s): Allen Loyd V Jr
Issue: Nov/Dec 2004 - Endotoxin
Page(s): 462-465
Abstract
Cough is a symptom of a number of pathologic conditions, including infections and pulmonary, cardiac, and gastrointestinal disorders. It also can be caused by medication. While numerous prescription and nonprescription treatments for cough are available, these are not suitable for all patients in all situations. Extemporaneous compounding allows preparation of customized formulations that contains a variety of difference components in a dosage form convenient for the patient. Formulas and methods are provided for several frequently prescribed compounds. The initial step in treating cough is eliminating exposure to any irritant or discontinuing any medication that might be causing the cough. Depending on the cause of the cough, drug therapies include antihistamines (with or without decongestant), intranasal or oral corticosteroids, antibiotics, bronchodilators, topical volatile agents (eg, camphor, menthol, thymol), guaifenesin (antitussive/expectorant), or centrally acting drugs that suppress the cough reflex (codeine sulfate, dextromorphan hydrobromide, hydrocodone bitartrate, hydromorphone hydrochloride).
Related Keywords
- continuing education
- coughing
- bronchial secretions
- antitussive effects
- central suppression
- medication side effect
- formulation: dextromorphan 30-mg capsules
- formulation: terpin hydrate and codeine elixir
- formulation: guaifenesin 100 mg/5 mL and promethazine hydrochloride 10 mg/5 mL cough syrup
- formulation: dextromorphan hydrobromide 20-mg lollipops with menthol and eucalyptus oil
- formulation: hydrocodone 5-mg or hydromorphone 1-mg troches
- formulation: codeine sulfate 15-mg suppositories
- formulation: dextromorphan 30-mg suppositories
- formulation: inhalant volatiles for vaporizers
Related Categories
- FORMULATIONS
Related Articles from IJPC
Issue/Page View/Buy |
Title/Author (Click for Abstract / Details / Purchase) |
---|---|
Nov/Dec 2004
Pg. 462-465
|
Author(s):
Allen Loyd V Jr
|
Mar/Apr 2003
Pg. 106-113
|
Author(s):
Davidson Gigi S
|
May/Jun 2004
Pg. 181-185
|
Author(s):
Hinkle Amanda R, Newton Gail D
|
Mar/Apr 2003
Pg. 129-134
![]() |
Author(s):
Allen Loyd V Jr
|
Sep/Oct 2001
Pg. 401-405
|
|
Nov/Dec 2012
Pg. 480-483
|
Author(s):
Allen Loyd V Jr
|
Nov/Dec 2015
Pg. 504
|
Author(s):
Allen Loyd V Jr
|
Sep/Oct 2005
Pg. 388
|
Author(s):
Allen Loyd V Jr
|
Sep/Oct 2005
Pg. 386
|
Author(s):
Allen Loyd V Jr
|
Sep/Oct 2005
Pg. 387
|
Author(s):
Allen Loyd V Jr
|
May/Jun 2013
Pg. 247-253
|
|
Nov/Dec 2022
Pg. 516-521
|
|
Mar/Apr 2010
Pg. 105-107
|
Author(s):
Williams LaVonn A
|
Mar/Apr 2010
Pg. 171-173
|
|
May/Jun 2009
Pg. 224-229
|
Author(s):
McElhiney Linda F
|
Jan/Feb 2017
Pg. 6-16
|
Author(s):
Deleruyelle Laura J
|
Jul/Aug 2003
Pg. 304
|
Author(s):
Allen Loyd V Jr
|
Jul/Aug 1999
Pg. 291-294
|
Author(s):
Allen Loyd V Jr
|
Sep/Oct 2017
Pg. 388-392
|
Author(s):
Allen Loyd V Jr
|
Mar/Apr 2012
Pg. 117-124
|
Author(s):
Zur Eyal
|